Stay updated on Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.

Latest updates to the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe site revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check17 days agoChange DetectedA banner was added announcing an NIH terminology transition, including the stated shift from “Artificial Intelligence” to “Super Intelligence.” The study page itself continues to show a 403 error.SummaryDifference1%

- Check24 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2, while the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check31 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check45 days agoChange DetectedData-sharing and study documentation references (e.g., IPD sharing details, CSR, SAP, protocol) have been removed from the page. The core trial information remains, but access to supplementary materials is now limited.SummaryDifference26%

- Check52 days agoChange DetectedRevision label updated from v3.6.6 to v3.7.0, signaling a page version update. This change reflects a versioned update to the page rather than a modification to study data or eligibility criteria.SummaryDifference0.0%

Stay in the know with updates to Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.